NASDAQ:SUPN - Supernus Pharmaceuticals Stock Price, Forecast & News

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) announced its earnings results on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.54 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.59 by $0.05. The specialty pharmaceutical company had revenue of $102.14 million for the quarter, compared to analyst estimates of $108.70 million. Supernus Pharmaceuticals had a return on equity of 21.02% and a net margin of 25.92%. The business's revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS. View Supernus Pharmaceuticals' Earnings History.

Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Supernus Pharmaceuticals.

7 analysts have issued 12 month price targets for Supernus Pharmaceuticals' shares. Their forecasts range from $23.00 to $65.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $47.33 in the next twelve months. This suggests a possible upside of 91.7% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.

Media headlines about SUPN stock have been trending negative on Wednesday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Supernus Pharmaceuticals.

Supernus Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 6,390,000 shares, an increase of 7.9% from the December 15th total of 5,920,000 shares. Based on an average trading volume of 703,400 shares, the days-to-cover ratio is currently 9.1 days. Currently, 12.6% of the shares of the company are sold short. View Supernus Pharmaceuticals' Current Options Chain.

Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Exelixis (EXEL), Netflix (NFLX), Cara Therapeutics (CARA), Sarepta Therapeutics (SRPT) and Pfizer (PFE).

Supernus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.46%), Ingalls & Snyder LLC (0.13%), State of Alaska Department of Revenue (0.08%), Louisiana State Employees Retirement System (0.03%), Measured Wealth Private Client Group LLC (0.02%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.

SUPN stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Ingalls & Snyder LLC, Nisa Investment Advisors LLC, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. View Insider Buying and Selling for Supernus Pharmaceuticals.

SUPN stock was bought by a variety of institutional investors in the last quarter, including Measured Wealth Private Client Group LLC. View Insider Buying and Selling for Supernus Pharmaceuticals.

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SUPN stock can currently be purchased for approximately $24.69.

Supernus Pharmaceuticals has a market capitalization of $1.30 billion and generates $408.90 million in revenue each year. The specialty pharmaceutical company earns $110.99 million in net income (profit) each year or $2.05 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.View Additional Information About Supernus Pharmaceuticals.

The official website for Supernus Pharmaceuticals is http://www.supernus.com/.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]